PCI in Diabetic Patients

Diabetes as a key risk factor for cardiovascular disease has and will continue to be a pressing
health issue, since:

  • The incidence of diabetes is sharply increasing worldwide.
  • The total number of people with diabetes is projected to rise from 285 million in 2010 to 439 million in 2030.2 
  • Nearly half of U.S. adults with diabetes, for example, fail to meet recommended guidelines for diabetes care.3 

Many diabetic patients will therefore undergo revascularization for coronary artery disease at some point in their lives. Yet because diabetic patients' risk of adverse events is higher than in nondiabetic patients,4 it is incumbent on physicians to implant a stent that will ensure long-term patient safety.


XIENCE Data in Diabetic Patients

Everolimus-Eluting Coronary Stents in Diabetes 

XIENCE Data in Diabetic Patients

Everolimus-Eluting Coronary Stents in Diabetes 


Multiple Trials Reveal XIENCE Stent Efficacy and Safety in Patients with Diabetes

Several recent stent trials reported on cohorts of diabetic patients—and they point to the solid performance of XIENCE in this patient population.


TUXEDO Trial Establishes XIENCE's Superiority in Diabetes Patients

“Everolimus-eluting stents [XIENCE] were superior to paclitaxel-eluting stents [Taxus] with regard to several endpoints, including target vessel failure, myocardial infarction and stent thrombosis.” 

—Upendra Kaul, MD, TUXEDO Trial9 

Unlike the studies illustrated above, the TUXEDO trial focused solely on patients with diabetes. The authors designed TUXEDO in this way since several prior stent trials were not sufficiently powered to determine if stent type affected outcomes.9

Event Rates at 2 Years

Compared to XIENCE, the results showed that TVF was consistently higher in the Taxus arm in most of the prespecified subgroups.9

Get the latest data

Sign up to receive the latest about XIENCE study results as they become available.


SIGN UP
Sign up

  1. Matheus AS. Int J Hypertens. 2013. doi: 10.1155/2013/653789.
  2. Mozaffarian D, et al. for the AHA. Circulation. 2015;133:e38-e360. doi: 10.1161/CIR.0000000000000350.
  3. Ali MK, et al. N Engl J Med. 2013;368:1613–1624.
  4. Tandjung K. TWENTE Trial. TCT 2012.
  5. Kaul U. TUXEDO Trial 2-year data. TCT 2016.  
  6. Based on percentage of diabetic patients in trials registered on clinicaltrials.gov. Data on file at Abbott Vascular.
  7. Jensen LO. SORT OUT IV Trial. ACC 2015.
  8. Slagboom T. BIOFLOW-II Trial. Euro PCR 2015.
  9. Kaul U, et al. TUXEDO Trial. N Engl J Med. 2015;373:1709-1719. doi: 10.1056/NEJMoa1510188. 

You are about to leave the Abbott family of websites for a third party website.

Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott.

The website that you have requested also may not be optimized for your screen size.

Do you wish to continue and exit the website?

Disclaimer

Xiencestent.com is a product-specific website that is NOT intended for U.S. residents. This web content is exclusively reserved for health care professionals in countries with applicable health authority product registrations.

If you are a resident of a country other than those to which the site is directed, please contact your local Abbott affiliate to obtain the appropriate product information for your country of residence.

Do you wish to continue to visit the International section of this website?